3
Announcements
Trials
Browse
Landscape
Status
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Interventions
Surveys and Questionnaires
7
Interviews as Topic
7
Blood Specimen Collection
5
Specimen Handling
4
Exercise Test
4
fludarabine
3
Voriconazole
3
Mental Status and Dementia Tests
3
Bortezomib
3
Standard of Care
2
Observation
2
Itraconazole
2
Flow Cytometry
2
Electronic Health Records
2
Data Collection
2
Antiviral Agents
2
posaconazole
1
liposomal amphotericin B
1
isavuconazole
1
glucarpidase
1
fludarabine phosphate
1
brexucabtagene autoleucel
1
axicabtagene ciloleucel
1
Whole-Body Irradiation
1
Watchful Waiting
1
Vincristine
1
Valganciclovir
1
Transplantation
1
Tomography, X-Ray Computed
1
Tomography, Optical Coherence
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Hematologic Neoplasms
×
Inosine Monophosphate
×
Clear all
NCT07474051
2026-03-16
PERSIST
AvenCell Therapeutics, Inc.
Enrolling by invitation
178 enrolled